氨茶碱与沙美特罗替卡松对COPDⅢ级稳定期患者影响分析

The clinical impact of Aminophylline combined with salmeterol on the treatment in patients with COPD Ⅲlevel stability

目的探讨氨茶碱联合沙美特罗替卡松应用在慢性阻塞性肺疾病Ⅲ级稳定期患者中对肺脏功能和生活质量的影响及应用价值。方法选择慢性阻塞性肺疾病Ⅲ级稳定期患者160例采取随机数字表法分为观察组和对照组,对照组给予氨茶碱治疗,观察组联合沙美特罗替卡松治疗,记录两组疗效对比。结果观察组治疗后FEV(12.29±0.86)L,FEV1/FVC(65.35±8.44)%;对照组治疗后FEV(11.88±0.52)L,FEV1/FVC(60.14±5.83)%,组间差异有统计学意义(P<0.05)。观察组治疗后症状维度(43.59±3.66)分,活动维度(60.32±3.09)分,影响维度(34.37±3.38)分;对照组治疗后症状维度(54.87±5.74)分,活动维度(70.68±5.49)分,影响维度(46.79±5.26)分,组间差异有统计学意义(P<0.05)。结论氨茶碱联合沙美特罗替卡松应用在慢性阻塞性肺疾病Ⅲ级稳定期患者能够改善患者生活质量,提高临床疗效。

Objective Explore the aminophylline combined salmeterol assigned application in patients with chronic obstructive pulmonary dis- ease III level plateau effect on lung function and quality of life and value of application. Methods To select 160 cases of patients with chronic ob- structive pulmonary disease III level plateau to random number table method was divided into observation group and control group, control group given aminophylline treatment, observation group combined salmeterol assigned treatment, two groups of curative effect comparison. Results The observation group was treated by FEV1 （2.29 ± 0.86） L, FEVJ FVC （65.35 ± 8.44）. The control group was treated with FEV± （1.88 ± 0.52） L, FEV± / FVC （60.14 ± 5.83） %, and the difference between the groups was statistically significant （P〈0.05）. The symptom dimension （43.59 ± 3.66） was ob- served in the observed group, and the activity dimension （60.32 ± 3.09） was observed, and the dimensions （34.37 ± 3.38） were observed. Dimension of the control group after treatment symptoms （54.87 ± 5.74） points, activity dimensions （70.68 ± 5.49） mm, affect the dimension （46.79 ± 5.26） points, comparing differences between groups was statistically significant （P〈0.05）. Conclusion Aminophylline combined salmeterol assigned ap- plication in patients with chronic obstructive pulmonary disease III level stability can improve patient quality of life, improve the clinical curative effect.